Catalyst Dossier · compiled by CeliA 🧫
Avidity Biosciences, Inc. (RNA)
Pharmaceutical Preparations · market cap $217M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-04-30 (est.)
Phase 2
Pipeline
5
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Avidity Biosciences (ticker: RNA) is a clinical-stage RNA therapeutics company with 391 employees and a ~$221M market cap trading near $12.91. Its lead asset, AOC 1001 (del-desiran), is in Phase 3 for myotonic dystrophy type 1 (DM1), with a binary Phase 3 data readout estimated around August 15, 2026 — the single most important near-term event for the stock. The company holds $267.8M in cash against a burn rate implying roughly 26 months of runway.
The catalyst path
- 2027-04-30 (est.)Phase 2 · AOC 1044imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| AOC 1001 (del-desiran) | Phase 3 | DM1 |
| AOC-1020 | Phase 3 | Facioscapulohumeral Muscular Dystrophy |
| AOC 1001 | Phase 2 | DM1 |
| AOC 1020 | Phase 2 | FSHD |
| AOC 1044 | Phase 3 | Duchenne Muscular Dystrophy |
Price & technical context
3-month
-3.2%
6-month
-82.4%
12-month
-72.0%
52-wk range
$11.18–$72.93
vs 50-day MA
+4.1%
vs 200-day MA
-65.6%
Realized vol
168.7%
Max drawdown
-84.7%
Daily closes through 2026-08-14. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RNA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.